Rheumatology (Oxford)

• 

  Publication Venue For

  • Longitudinal association of infrapatellar fat pad signal intensity alteration with biochemical biomarkers in knee osteoarthritis..  62:439-449. 2022
  • Improving outcomes in scleroderma: recent progress of cell-based therapies. 2022
  • Lymphocyte subset abnormalities in early severe scleroderma favor a Th2 phenotype and are not altered by prior immunosuppressive therapy..  61:4155-4162. 2022
  • Metabolomics analysis identifies a lipidomic profile in treatment-naïve juvenile dermatomyositis patients vs healthy control subjects..  61:1699-1708. 2022
  • Extracutaneous involvement is common and associated with prolonged disease activity and greater impact in juvenile localized scleroderma..  60:5724-5733. 2021
  • Preliminary evidence on abatacept safety and efficacy in refractory juvenile localized scleroderma..  60:3817-3825. 2021
  • ADA2 deficiency (DADA2) associated with Evans syndrome and a severe ADA2 genotype..  60:e237-e239. 2021
  • Conducting research in psoriatic arthritis: the emerging role of patient research partners..  59:i47-i55. 2020
  • Deficiency of adenosine deaminase 2: a case series revealing clinical manifestations, genotypes and treatment outcomes from Turkey..  59:254-256. 2020
  • Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors..  58:vii59-vii67. 2019
  • Treatment failure in inflammatory arthritis: time to think about syndemics?.  58:1526-1533. 2019
  • The SLE-key test serological signature: new insights into the course of lupus..  57:1632-1640. 2018
  • Power in numbers..  57:v40-v47. 2018
  • The new FDA labeling rule: impact on prescribing rheumatological medications during pregnancy..  57:v2-v8. 2018
  • Challenges and controversies of complex interventions in osteoarthritis management: recognizing inappropriate and discordant care..  57:iv88-iv98. 2018
  • The impact of menopause on functional status in women with rheumatoid arthritis..  57:798-802. 2018
  • Cardiovascular and cerebrovascular comorbidities of juvenile dermatomyositis in US children: an analysis of the National Inpatient Sample..  57:694-702. 2018
  • 2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects..  56:1884-1893. 2017
  • Transcriptional profiles of JIA patient blood with subsequent poor response to methotrexate..  56:1542-1551. 2017
  • Biosimilars in rheumatology: understanding the rigor of their development..  56:187-197. 2017
  • Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab..  56:247-254. 2017
  • Cartilage biomarkers in the osteoarthropathy of alkaptonuria reveal low turnover and accelerated ageing..  56:156-164. 2017
  • Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab..  55:1710. 2016
  • Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab..  55:991-999. 2016
  • Novel compound heterozygous variants in CECR1 gene associated with childhood onset polyarteritis nodosa and deficiency of ADA2..  55:1145-1147. 2016
  • Suppression of inflammatory disease activity in rheumatoid arthritis is associated with improvements in retinal microvascular health..  55:246-251. 2016
  • Nephrogenic systemic fibrosis is associated with hypophosphataemia: a case-control study..  53:1613-1617. 2014
  • Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study..  51:2204-2214. 2012
  • Microparticles as mediators and biomarkers of rheumatic disease..  51:1737-1746. 2012
  • Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial..  51:1628-1638. 2012
  • Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX..  51:1226-1234. 2012
  • Updating the 2003 European regulatory requirements for registering disease-modifying drugs to be used in the treatment of rheumatoid arthritis..  50:1732-1736. 2011
  • Retinal vascular calibre is altered in patients with rheumatoid arthritis: a biomarker of disease activity and cardiovascular risk?.  50:939-943. 2011
  • A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis..  48:1114-1121. 2009
  • Health-related quality of life in children and adolescents with juvenile localized scleroderma..  48:670-672. 2009
  • A large kindred of early-onset osteoarthritis of the knee and hip: excluding the link to COL2A1 gene..  48:371-374. 2009
  • The prevention, screening and treatment of congenital heart block from neonatal lupus: a survey of provider practices. 2018